Nothing Special   »   [go: up one dir, main page]

EA201892007A1 - 3-дезоксипроизводное и фармацевтические композиции на его основе - Google Patents

3-дезоксипроизводное и фармацевтические композиции на его основе

Info

Publication number
EA201892007A1
EA201892007A1 EA201892007A EA201892007A EA201892007A1 EA 201892007 A1 EA201892007 A1 EA 201892007A1 EA 201892007 A EA201892007 A EA 201892007A EA 201892007 A EA201892007 A EA 201892007A EA 201892007 A1 EA201892007 A1 EA 201892007A1
Authority
EA
Eurasian Patent Office
Prior art keywords
basis
pharmaceutical compositions
desoxy derivatives
desoxy
derivatives
Prior art date
Application number
EA201892007A
Other languages
English (en)
Other versions
EA038632B1 (ru
Inventor
Роберто Пелличари
Антимо Джойелло
Original Assignee
Интерсепт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интерсепт Фармасьютикалз, Инк. filed Critical Интерсепт Фармасьютикалз, Инк.
Publication of EA201892007A1 publication Critical patent/EA201892007A1/ru
Publication of EA038632B1 publication Critical patent/EA038632B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J11/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

В данной заявке предусматривается соединение (1)или его фармацевтически приемлемая соль или конъюгат с аминокислотой. Настоящее изобретение относится к активатору FXR и к способам получения и применения указанного соединения.
EA201892007A 2016-03-11 2017-03-07 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr) EA038632B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662306914P 2016-03-11 2016-03-11
PCT/US2017/021194 WO2017156024A1 (en) 2016-03-11 2017-03-07 3-desoxy derivative and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
EA201892007A1 true EA201892007A1 (ru) 2019-01-31
EA038632B1 EA038632B1 (ru) 2021-09-27

Family

ID=59787771

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892007A EA038632B1 (ru) 2016-03-11 2017-03-07 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)

Country Status (21)

Country Link
US (3) US10815267B2 (ru)
EP (1) EP3426348B1 (ru)
JP (1) JP6892457B2 (ru)
KR (1) KR102359191B1 (ru)
CN (1) CN108883305B (ru)
AR (1) AR107864A1 (ru)
AU (1) AU2017229481B2 (ru)
BR (1) BR112018068278B1 (ru)
CA (1) CA3016875C (ru)
EA (1) EA038632B1 (ru)
ES (1) ES2874682T3 (ru)
HK (1) HK1259145A1 (ru)
IL (1) IL261548B (ru)
MX (1) MX2018010983A (ru)
PH (1) PH12018501956A1 (ru)
PL (1) PL3426348T3 (ru)
PT (1) PT3426348T (ru)
SG (1) SG11201807784SA (ru)
SI (1) SI3426348T1 (ru)
TW (1) TWI772289B (ru)
WO (1) WO2017156024A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215179A4 (en) 2014-11-06 2018-07-25 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2015353473A1 (en) 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
RU2017130466A (ru) 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
LT3277286T (lt) 2015-03-31 2021-07-26 Enanta Pharmaceuticals, Inc. Tulžies rūgšties dariniai kaip fxr/tgr agonistai, ir jų panaudojimo būdai
EP3359160B1 (en) 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
PL3426348T3 (pl) 2016-03-11 2022-01-03 Intercept Pharmaceuticals, Inc. Pochodna 3-dezoksylowa i jej kompozycje farmaceutyczne
US10584145B2 (en) 2016-11-29 2020-03-10 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
ES2971092T3 (es) 2017-04-07 2024-06-03 Enanta Pharm Inc Procedimiento para la preparación de derivados de ácidos biliares de carbamato de sulfonilo
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN119136794A (zh) * 2022-04-21 2024-12-13 英特塞普特医药品公司 法尼醇x受体激动剂的用途
WO2024097247A1 (en) * 2022-10-31 2024-05-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2712617T1 (sl) * 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
US20130261317A1 (en) 2010-09-27 2013-10-03 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
WO2013098191A1 (en) 2011-12-29 2013-07-04 Novo Nordisk A/S Dipeptide comprising a non-proteogenic amino acid
PL3360882T3 (pl) * 2013-05-14 2021-10-25 Intercept Pharmaceuticals, Inc. 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu X
HUE048351T2 (hu) * 2014-05-29 2020-07-28 Bar Pharmaceuticals S R L Kolán-származékok alkalmazása FXR és TGR5/GPBAR1 mediált betegségek kezelésére és/vagy prevenciójára
BR112018002499A2 (pt) 2015-08-07 2018-09-18 Intercept Pharmaceuticals Inc método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
PL3426348T3 (pl) 2016-03-11 2022-01-03 Intercept Pharmaceuticals, Inc. Pochodna 3-dezoksylowa i jej kompozycje farmaceutyczne

Also Published As

Publication number Publication date
IL261548B (en) 2021-02-28
WO2017156024A1 (en) 2017-09-14
AR107864A1 (es) 2018-06-13
SG11201807784SA (en) 2018-10-30
AU2017229481B2 (en) 2022-06-16
EP3426348B1 (en) 2021-05-05
HK1259145A1 (zh) 2019-11-29
BR112018068278B1 (pt) 2023-12-19
KR20180117702A (ko) 2018-10-29
US11319337B2 (en) 2022-05-03
CN108883305A (zh) 2018-11-23
EA038632B1 (ru) 2021-09-27
ES2874682T3 (es) 2021-11-05
IL261548A (en) 2018-11-29
EP3426348A1 (en) 2019-01-16
JP6892457B2 (ja) 2021-06-23
PT3426348T (pt) 2021-06-28
PH12018501956A1 (en) 2019-06-17
EP3426348A4 (en) 2019-11-20
JP2019507781A (ja) 2019-03-22
KR102359191B1 (ko) 2022-02-04
US20170260225A1 (en) 2017-09-14
SI3426348T1 (sl) 2021-11-30
MX2018010983A (es) 2019-01-21
US10815267B2 (en) 2020-10-27
TW201734031A (zh) 2017-10-01
PL3426348T3 (pl) 2022-01-03
BR112018068278A2 (pt) 2019-04-02
CA3016875A1 (en) 2017-09-14
CA3016875C (en) 2023-08-22
AU2017229481A1 (en) 2018-09-20
US20210101927A1 (en) 2021-04-08
US20190002493A1 (en) 2019-01-03
TWI772289B (zh) 2022-08-01
CN108883305B (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
JOP20200122A1 (ar) مركبات مفيدة لتثبيط cdk7
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
PH12016501693A1 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
UA118673C2 (uk) Похідні 11-гідроксилу жовчних кислот та їх амінокислотні кон'югати як модулятори фарнезоїдного x-рецептора
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201891342A1 (ru) Изоиндольные соединения
EA201790046A1 (ru) Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης